Epigral Q3 FY26 results (Oct–Dec 2025) and concall

Chemicals · Concall AI · Call held 3 Feb 2026

Company page: Epigral share price, financials & guidance record

Epigral reported a mixed Q3 FY26 with marginal revenue growth and a positive shift towards specialty products. However, profitability was impacted by lower realizations, higher raw material costs, and inventory, leading to a significant drop in EBITDA and PAT. Management expressed confidence in a demand recovery from Q4 FY26 and the long-term growth prospects from ongoing capacity expansions and new projects.

You’re reading a preview. Opening the full call uses 1 concall credit.

What they filed

Q3 FY26: revenue down 7.4%, net profit down 62.5% against the same quarter last year.

₹ Cr · quarterly

Line item	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26	Q3 FY26
Revenue	626	645	628	607	587 −6%	597 −7%
Expenses	448	463	454	443	455	494
EBITDA	178	183	173	163	132 −26%	103 −44%
Margin	28%	28%	28%	27%	22%	17%
Other income	6	4	4	9	2	6
Interest	27	0	12	23	22	11
Depreciation	32	33	34	42	42	43
Profit before tax	125	154	131	107	70 −44%	55 −64%
Tax rate	35%	33%	34%	-50%	26%	28%
Net profit	81	104	87	161	51 −37%	39 −62%
EPS	19.57	24.02	20.14	37.25	11.87	9.07

How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.

What they filed

More Chemicals earnings calls